X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PDS Biotech and Farmacore have jointly prioritized advancement of PDS0203 to human clinical trials. PDS Biotech had previously announced the parallel development of two Versamune®-based COVID-19 vaccines PDS0203 and PDS0204 each containing different SARS-CoV-2 proteins.
Lead Product(s): PDS0203
Therapeutic Area: Infections and Infectious Diseases Product Name: PDS0203
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: PDS Biotechnology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
Under the collaboration, PDS Biotech and Farmacore will accelerate development of Versamune®-CoV-2FC into Phase 1 clinical testing in Brazil, with initial financial support provided by the Brazilian Ministry of Science, Technology, Innovation and Communication (MCTIC).
Lead Product(s): PDS0204
Therapeutic Area: Infections and Infectious Diseases Product Name: PDS0204
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: MCTIC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
